WOMEN COINFECTED WITH HIV AND VHC. PART 1. PSYCHOSOCIAL CHARACTERISTIC AND READINESS TO ANTIVIRAL THERAPY

The objective of the present study was the analysis of medical and social status of women co-infected with HIV and VHC with the following assessment of their readiness to antiviral therapy of chronic hepatitis C virus infection (CHC) taking into account the mental health and living conditions and sustaining the adherence to antiviral therapy thereafter. Materials and methods. To clarify the social and psychological status, 100 outpatient cards of women co-infected with HIV/HCV were analyzed. The in-depth study with the assessment of the psychosocial and detoxification status and the adherence to antiretroviral therapy (ART) was held in fifty patients. Results. Most of the women had a long-standing history of HIV infection and HCV. Of these, 78% underwent ART and 84,6% had a high adherence to treatment. The main social problems of the women were connected with their work (34,2%) and family circumstances (26,3%). An increase in the concentration of carbohydrate-deficient transferrin (CDT), the marker of chronic alcohol abuse, was detected in three of 50 patients, and other three of the 50 had this parameter in the zone of unstable values. 72% of the patients showed mental disorders, while more than half of them (60%) had actively used psychoactive substances, and organic symptomatic mental disorder effects were observed in 20% of the patients. Most of the women were in remission on the use of psychoactive substances. Evaluation of the depression and anxiety levels has showed scattered results but in the meantime 54% of the women expressed complaints of asthenic nature, anxious mood was marked in 38% of the patients, 40% of them earlier had been suicidally inclined. Conclusion. Taking into account the social problems in one-third of patients that may negatively affect the treatment of HCV and HIV infection, it is essential to lend complimentary psychological support and assist with solving difficulties before the treatment assignment in order to increase the adherence to treatment. Due to mental health reasons, the patients need continuous observation and periodic condition correction. The majority of surveyed agree ART of CHC at this moment and in the short term but carefully relate to offered treatment regimens and its duration. Given the mental state of the patients, it can be assumed that virus C in women with HIV/HCV co-infection should be treated with direct-acting antiviral agents that do not exacerbate existing disorders. The next issue of the journal .HIV infection and immunosuppression disorders. (2018. Vol. 10, No. 4) will present the results of the study of clinical status features and the prospects for the therapy.

HIV infection (HIV), hepаtitis C virus (HCV), chronic virus hepatitis C (CHC), co-infection with HIV/HCV, women, social status, psychopathological condition, antiretroviral therapy (ART), antiviral therapy (AVT)

1. The coinfection HIV/HCV: etiology, epidemiology, pathogenesis, clinic, diagnostics, treatment. Ed. N.Matievskaya. Grodno: Grodno state medical University, 2013, 352 c. (In Russ.).

2. Platt L., Easterbrook P., Gower E., McDonald B., Sabin K., McGowan C., Yanny I., Razavi H., Vickerman P. Prevalence and burden of HCV coinfection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect. Dis., 2016, Vol. 16, No. 7, pp. 797–808.

3. Alter M.J. Epidemiology of viral hepatitis and HIV co-infection J. Hepatology, 2006, Vol. 44, pp. 6–9.

4. Woman, child and HIV. Eds. N.A.Belyakov, N.Yu.Rakhmanina, A.G.Rakhmanova. Saint-Petersburg: Baltic medical education center, 2012, 600 p. (In Russ.).

5. Yastrebova E.B., Gutova L.V. Analysis of clinical, anamnestic and immunological indicators in women of reproductive age with HIV infection and chronic viral hepatitis C. HIV Infection and Immunosuppressive Disorders, 2016, Vol. 8, No. 2, pp. 39–46 (In Russ.).

6. Marine-Barjoan E., Berrebi A., Giordanengo V. et al. HCV/HIV co-infection, HCV viral load and mode of delivery: risk factors for mother-to-child transmission of hepatitis C virus? AIDS, 2007, Vol. 21 (13), pp. 1811–1815.

7. McMenamin M.B., Jackson A.D., Lambert J. et al. Obstetric management of hepatitis C-positive mothers: analysis of vertical transmission in 559 mother-infant pairs. Am. J. Obstet. Gynecol., 2008, Vol. 199 (3), pp. 311–315.

8. Mast E.E., Hwang L.Y., Seto D.S. et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J. Infect. Dis., 2005, Vol. 192 (11), pp. 1880–1889.

9. Benova L., Mohamoud Y.A., Calvert C., Abu-Raddad L.J. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin. Infect. Dis., 2014, Vol. 59 (6), pp. 765–773.

10. Lioznov D.A. Comorbidity blood-contact viral infections and drug induced diseases in persons of young age. Extended abstract of Doctor’s thesis: 14.01.09. Saint-Petersburg, 2010, 42 p. (In Russ.).

11. Medical and social consequences of injecting drug use in Russia. Ed. V.V.Kirzhanova. Moscow, 2009, 319 p. (In Russ.).

12. Miller C.L., Wood E., Spittal P.M., Li K., Frankish J.C., Braitstein P. et al. The future face of coinfection: prevalence and incidence of HIV and hepatitis C virus coinfection among young injection drug users. J. Acquir. Immune Defic. Syndr., 2004, Vol. 36 (2), pp. 743–749.

13. Frederick T., Burian P., Terrault N. et al. Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women’s Interagency HIV Study (WIHS). AIDS Patient Care STDs, 2009, Vol. 23, pp. 915–923.

14. Barinova A.N., Plavinskiy S.L., Vinogradova N.H. Use of one-time data to assess the intensity of infection of injecting drug users with HIV infection and viral hepatitis C — lack of constant risk. Bulletin of the North-West State Medical University named after I.I.Mechnikov, 2015, Vol. 7, No. 1, pp. 78–87 (In Russ.).

15. Safonova P.V., Rassokhin V.V., Diclemente R.J. Past experience with psychoactive substances and present-day risk behaviour in HIV-infected women. HIV Infection and Immunosuppressive Disorders, 2014, Vol. 6, No. 4, pp. 24–34 (In Russ.).

16. Bulekov I.S., Samarina A.V. Features of behavior of HIV-infected women dependent on psychoactive substances. HIV Infection and Immunosuppressive Disorers, 2012, Vol. 4, No. 1, pp. 32–41 (In Russ.).

17. The human immunodeficiency virus — medicine. Eds. N.A.Belyakov and A.G. Rakhmanova. Saint-Petersburg: Baltic medical education center, 2011, 656 p. (In Russ.).

18. Hoffman C., Rockstroh J.K. HIV 2015/2016. Medicin focus verlag, Hamburg, 2015, 755 p. URL: http://www.hibook.com

19. Khokhlova A.V. Viral hepatitis combined with HIV infection in autopsy material. HIV Infection and Immunosuppressive Disorders, 2015, Vol. 7, No. 2, pp. 77–84 (In Russ.).

20. Benhamou Y., Bochet M., Martino D. Liver fibrosis progression in human immunodeficiency virus and hepatitis С virus coinfected patients: the Multivirc Group. J. Hepatology, 1999, Vol. 30, No. 4, pp. 1054–1058.

21. Leonova O.N., Stepanova Ye.V., Belyakov N.A. Severe comorbid conditions in patients with HIV infection: analysis of adverse outcomes. HIV Infection and Immunosuppressive Disorders, 2017, Vol. 9, No. 1, pp. 55–64 (In Russ.).

22. Soriano V., Vispo E., Labarga P., Medrano J., Barreiro P. Viral hepatitis and HIV co-infection. Antiviral Res., 2010, Vol. 85, pp. 303–315.

23. Asselah T., Marcellin P., Schinazi R.F. Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure? Liver Int., 2018, Vol. 38, Suppl. 1, pp. 7–13. DOI: 10.1111/liv.13673.

24. Yushchuk N.D., Klimova E.A. Treatment of chronic hepatitis C in Russia: current opportunities and immediate prospects. Infectious Diseases: News, Opinions, Training, 2017, No. 2 (19), pp. 86–95 (In Russ.).

25. Sagalova O.I. Non-Interferon antiviral therapy of chronic hepatitis C. Epidemiology and Infectious Diseases. Topical Issue, 2015, No. 2, pp. 41–51 (In Russ.).

26. Zhdanov K.V., Lobzin Yu.V., Gusev D.A., Kozlov K.V. Viral hepatitis. Saint-Petersburg: Folio, 2011, 304 p. (In Russ.).

27. Manapova E.R., Fazylov V.H., Beshimov A.T. Effectiveness of antiviral therapy of chronic hepatitis C in patients with combined HCV/HIV infection in a comparative aspect. Infectious Diseases: News, Opinions, Training, 2017, No. 4 (21), pp. 51–56 (In Russ.).

28. Recommendations for the diagnosis and treatment of adult patients with hepatitis C. Ed. V.T.Ivashkin and N.D.Yushchuk. Moscow: GEOTAR-Media, 2015, 144 p. (In Russ.).

29. New recommendations for treatment of viral hepatitis C. EASL 2016/EASL. WHO, 2017 (In Russ.).

30. Azovtzeva O.V., Arkhipov G.S., Trofimova T.N. Pegylated interferon and ribavirin as an available option of antiviral therapy of chronic hepatitis C in HIV-infected. HIV Iinfection and Immunosuppressive Disorders, 2017, Vol. 9, No. 3, pp. 39–46 (In Russ.).

31. Rasskazova V.N., Luchaninova V.N., Krivelevich V.Ya., Rasskazova M.E. Medical and social characteristics of health features of HIV-positive pregnant women and their children. Pacific Medical Journal, 2011, No. 3, pp. 32–33 (In Russ.).

32. Tabolina A.V., Filimonova E.V. Psychological features of women with HIV-positive and HIV-negative status. Proceedings of the XIV International Scientific-Practical Conference .Scientific forum: Pedagogy and psychology., No. 1 (14), Moscow: MCNO, 2018, pp. 85–89 (In Russ.).

33. New Recommendations in updated WHO Guidelines for the screening, care and treatment of persons with chronic Hepatitis C Infection. WHO, April 2016, 138 p.

34. Zhdanov K.V., Kozlov K.V. Clinical advantages and economic efficiency of antiviral therapy in patients with chronic hepatitis C in the conditions of public health. HIV Infection and Immunosuppressive Disorders, 2016, Vol. 8, No. 2, pp. 77–83 (In Russ.).

35. Baros A.M., Wright T.M., Latham P.K., Miller P.M., Anton R.F. Alcohol consumption, % CDT, GGT and blood pressure change during alcohol treatment. Alcohol and Alcoholism, 2008, Vol. 43, No. 2, pp. 192.

36. Atabaeva G.G., Seidualieva B.S., Kurbanova E.A. Electrophoresis of carbohydrate-deficient transferrin fractions (CDT) as a marker of chronic alcohol abuse. Bulletin of the Almaty State Institute of Advanced Medical Training, 2011, No. 2 (14), pp. 37 (In Russ.).

37. Helander A. Chromatographic measurement of transferring glycoforms for detecting alcohol abuse and congenital disorders of glycosylation. In: Chromatographic methods in clinical chemistry and toxicology. John Wiley & Sons Ltd, Hoboken, N.J., USA, 2007, 310 p., pp. 87–97.

38. Stasiskis T.A., Dunayeva N.V., Kovelenov A.Yu. Safety of antiviral therapy of chronic viral hepatitis With pegylated interferon and ribavirin in patients with HIV infection receiving HAART. HIV Infection and Immunosuppressive Disorders, 2015, Vol. 7, No. 2, pp. 27–40 (In Russ.).

39. Ulyukin I.M., Rassokhin V.V. Neuro-psychiatric disorders in patients with chronic parenteral hepatitis. HIV Infection and Immunosuppressive Disorders, 2015, Vol. 7, No. 1, pp. 16–28 (In Russ.).

40. Ivanets N.N., Kinkulysina M.A., Avdeeva T.I., Tikhonova Yu.G., Volkov A.V., Morozov D.I. Depression with antiviral therapy for chronic hepatitis C. Diagnosis and differential treatment. Moscow: Medical News Agency, 2015, 280 p. (In Russ.).